Immunotheraphy for the Treatment of Breast Cancer

Publication Date: June 30, 2021
Last Updated: March 14, 2022

Immunotherapy With PD-(L)1 Inhibitors for the Treatment of Advanced/Metastatic Breast Cancer

Clinical trial enrollment remains a priority to further understand the benefit of checkpoint inhibition in metastatic breast cancer.
()
1317519

Emerging Data on Immunotherapy With PD-(L)1 Inhibitors for Early-Stage/Locally Advanced Breast Cancer

For all patients with stage II and III TNBC, clinical trial enrollment should be considered if available.
()
1317519

Overview

Title

Immunotheraphy for the Treatment of Breast Cancer

Authoring Organization